NCT03870776View on ClinicalTrials.gov

RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

December 1, 2024

Study Completion Date

March 1, 2025

Conditions
Depression
Interventions
DRUG

MAP4343

Daily oral administration of MAP4343

DRUG

Placebo

Daily oral administration of Placebo

Trial Locations (10)

25000

CHU Besançon, Besançon

37000

CHRU Tours, Tours

44000

CHU Nantes, Nantes

49900

CHU Angers, Angers

59000

Hôpital Fontan 1, Lille

75013

APHP Hôpital La Pitié Salpétrière - Prinicipal investigator center, Paris

75014

Hôpital Ste Anne, Paris

78990

Cabinet Médical Ambroise Paré, Élancourt

85000

CHD Vendée, La Roche-sur-Yon

86000

CHU Henri Laborit, Poitiers

Sponsors

Lead Sponsor

Mapreg
All Listed Sponsors
collaborator

Eurofins Optimed

INDUSTRY

lead

Mapreg

INDUSTRY

NCT03870776 - RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode | Biotech Hunter | Biotech Hunter